美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

減肥藥

1,470.07

-22.1052-1.48%

漲家數：4

跌家數：3

平家數：- -

市盈率：- -

高：1,485.06

開：1,483.83

低：1,455.39

收：1,492.17

資料載入中...

總覽新聞資訊

美FDA宣佈司美格魯肽不再短缺，為何諾和諾德(NVO.US)股價大漲？

智通财经网

中國研究人員發現蝙蝠病毒進入人類細胞的途徑與 COVID 相同

碩迪生物盤中異動股價大漲5.13%

Viking Therapeutics, Inc.盤中異動股價大漲5.22%

BUZZ-Alvotech 在美國推出生物仿製藥後大漲

【MSCI北歐國家指數收漲超1%，諾和諾德漲約6%，美國藥監局稱減肥藥供應短缺問題得到處置】明晟公司MSCI北歐國家指數漲1.3%，創2月6日以來最佳單日表現，報389.62點，本週累計上漲將近3.16%。諾和諾德漲5.8%，領跑一眾成分股。2月21日稍早，美國食品藥品管理局宣稱，減肥和糖尿病藥物Ozempic短缺已得到解決，諾和諾德現在可以滿足全美範圍內對Ozempic和Wegovy的需求。巴克萊分析師Emily Field在報告中寫道，這對諾和諾德來説非常重要，因為其擴大規模的努力已經達到了“公司現在能夠供應市場”的程度。

諾和諾德股價上漲此前FDA表示Ozempic短缺已得到解決

环球市场播报

諾和諾德的 Wegovy 和 Ozempic 從美國 FDA 的短缺藥品名單中刪除，複方製劑生產商收到通知

安進漲0.69% 股價突破300美元大關

諾和諾德(NVO.N)：美國食品藥品監督管理局（FDA）批准的所有劑量的司美格魯肽（semaglutide）正在持續出貨

諾和諾德(NVO)反覆升近4% 美國FDA稱司美格魯肽注射液Ozempic短缺已得到解決

特朗普媒體科技集團(DJT.O)漲2%，公司董事會投票決定推進擴張計劃。諾和諾德(NVO.N)漲4.9%，美國食品藥品管

諾和諾德(NVO.N)盤前上漲5.5%，美國食品藥品監督管理局（FDA）稱，司美格魯肽注射液Ozempic短缺已得到解決

隱瞞關鍵信息，諾和諾德索賠8.3億美元

国际金融报

禮來(LLY.US)新一代減肥藥可顯著減重副作用同樣明顯

21健訊Daily 丨降糖版司美格魯肽或致失明？諾和諾德回應；真實生物再闖港交所

21世纪经济报道

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4599/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"減肥藥","latestPrice":1470.068,"timestamp":1741294799999,"preClose":1492.1732,"halted":0,"volume":66900686,"delay":0,"changeRate":-0.014814,"change":-22.105225,"pbRate":11.780703,"amount":5866961806.496502,"amplitude":0.019884,"prevYearClose":1305.0607,"fiveDayClose":1460.4895,"twentyDayClose":1394.0055,"turnoverRate":0.006338,"marketCap":1580708443232,"floatMarketCap":1468183266688,"peRate":41.703544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1485.0612,"amplitude":0.019884,"preClose":1492.1732,"low":1455.3911,"pbRate":"11.780703","latestPrice":1470.068,"volume":66900686,"delay":0,"open":1483.8325,"prevYearClose":1305.0607,"prevWeekClose":1482.1702,"prevMonthClose":1482.1702,"prevQuarterClose":1305.0607,"fiveDayClose":1460.4895,"twentyDayClose":1394.0055,"sixtyDayClose":1438.0239,"secType":"PLATE","market":"US","turnoverRate":0.006338,"peRate":41.703544,"marketCap":1580708443232,"floatMarketCap":1468183266688,"timestamp":1741294799999,"nameCN":"減肥藥"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":4,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:16,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2513228246","title":"美FDA宣佈司美格魯肽不再短缺，為何諾和諾德(NVO.US)股價大漲？","url":"https://stock-news.laohu8.com/highlight/detail?id=2513228246","media":"智通财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513228246?lang=zh_tw&edition=fundamental","pubTime":"2025-02-22 10:54","pubTimestamp":1740192840,"startTime":"0","endTime":"0","summary":"当地时间周五，美国食品和药物管理局官网显示，诺和诺德公司报告称司美格鲁肽注射液的短缺和停产情况已经解决。FDA称，诺和诺德现在可以在美国全国范围内满足患者的药物需求。之前有银行家估计，如果司美格鲁肽持续短缺，仿制地减肥药每年能为制造商带来高达10亿美元的收入。去年12月，FDA宣布司美格鲁肽的竞争对手、礼来替尔泊肽的短缺问题已经解决。之后，外包设施协会将FDA告上法庭，他们认为FDA忽视了药物仍然短缺的证据。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"be3201d4ba339139b8fa1c56337988b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkstocknews/2025-02-22/doc-inemikpk2851260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4532","BK4599","LU0154236417.USD","BK4007","BK4585","BK4588","LU1093756168.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","NVO","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2513245187","title":"中國研究人員發現蝙蝠病毒進入人類細胞的途徑與 COVID 相同","url":"https://stock-news.laohu8.com/highlight/detail?id=2513245187","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513245187?lang=zh_tw&edition=fundamental","pubTime":"2025-02-22 06:51","pubTimestamp":1740178309,"startTime":"0","endTime":"0","summary":"中国研究人员发现蝙蝠病毒进入人类细胞的途径与 COVID 相同Julie Steenhuysen/Nancy Lapid路透社2月21日 - 中国研究人员报告说，一种新发现的蝙蝠冠状病毒与导致COVID-19的SARS-CoV-2病毒一样，使用相同的细胞表面蛋白进入人体细胞，这使它有一天可能传播给人类。在进一步的实验中，研究人员发现了针对蝙蝠病毒的单克隆抗体和抗病毒药物。彭博社周五早些时候报导了这项研究，并称这篇发现蝙蝠病毒的论文推动了COVID疫苗生产商的股价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3T3PC1X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","IE0002270589.USD","LU1023059063.AUD","IE00BLSP4452.SGD","IE00BBT3K403.USD","BK4534","MRNA","LU0122379950.USD","LU1894683264.USD","BK4592","BK4588","LU1894683348.USD","LU0289739699.SGD","LU0868494617.USD","LU1066053197.SGD","NVAX","LU1057294990.SGD","SG9999002224.SGD","BK4139","BK4547","SG9999002232.USD","SG9999011175.SGD","LU0321505439.SGD","SG9999001176.SGD","BK4532","BK4007","IE00B19Z3581.USD","LU0306806265.USD","LU0321505868.SGD","BK4585","LU1066051498.USD","LU0170899867.USD","LU0306807586.USD","LU0225284248.USD","LU1883839398.USD","BK4548","BK4581","IE00B19Z3B42.SGD","SG9999003800.SGD","IE000M9KFDE8.USD","BK4568","LU0058720904.USD","SGXZ57979304.SGD","BK4551","LU0456855351.SGD","PFE","BK4533","BK4599","LU0985481810.HKD","LU0234572021.USD"],"gpt_icon":1},{"id":"2513521520","title":"碩迪生物盤中異動 股價大漲5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513521520","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513521520?lang=zh_tw&edition=fundamental","pubTime":"2025-02-22 01:29","pubTimestamp":1740158978,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日01时29分，硕迪生物股票出现异动，股价急速上涨5.13%。截至发稿，该股报24.59美元/股，成交量27.7175万股，换手率0.48%，振幅4.45%。机构评级方面，在所有11家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体涨幅为0.36%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222012938abd7d517&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222012938abd7d517&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","GPCR","BK4599"],"gpt_icon":0},{"id":"2513218261","title":"Viking Therapeutics, Inc.盤中異動 股價大漲5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513218261","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513218261?lang=zh_tw&edition=fundamental","pubTime":"2025-02-22 01:23","pubTimestamp":1740158624,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日01时23分，Viking Therapeutics, Inc.股票出现波动，股价快速拉升5.22%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。公司临床方案管线包括VK2809、VK5211、VK0214产品。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222012345988e0421&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222012345988e0421&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LENZ","VKTX","BK4588","BK4139","BK4599"],"gpt_icon":0},{"id":"2513629053","title":"BUZZ-Alvotech 在美國推出生物仿製藥後大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2513629053","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513629053?lang=zh_tw&edition=fundamental","pubTime":"2025-02-22 00:51","pubTimestamp":1740156719,"startTime":"0","endTime":"0","summary":"** 继1月份安进公司AMGN.O推出Wezlana之后， ，这标志着Stelara的第二个生物仿制药上市，预计Biocon BiologicsBIOC.NS和费森尤斯卡比公司FRES.M3将很快跟进。** 瑞银分析师认为，新产品的推出是未来生物仿制药的成功之路；预计到 2028 年，全球销售额将达到 3.9 亿美元 ** ALVO的股价今年以来下跌了约7%，而TEVA下跌了24%。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3S3PC1IR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","LU1221951046.USD","LU2242652126.USD","JNJ","BK4533","IE00B1BXHZ80.USD","LU1935042991.SGD","LU0098860793.USD","LU2505996681.GBP","IE00BJT1NW94.SGD","LU1914381329.SGD","LU1732800096.USD","LU2129689431.USD","LU2430703251.USD","LU0912757837.SGD","LU1244550221.USD","BK4592","LU0234572021.USD","BK4566","LU1430594728.SGD","IE00B19Z3581.USD","BK4550","LU0114720955.EUR","LU0320765646.SGD","IE000M9KFDE8.USD","LU1778281490.HKD","BK4559","ALVO","IE00BVYPNW00.USD","LU1506573853.SGD","LU0792757196.USD","IE00BFTCPJ56.SGD","SG9999002232.USD","LU1066051225.USD","IE00BVYPNV92.GBP","LU1196500208.SGD","LU1894683264.USD","LU0868494617.USD","LU2505996509.AUD","IE00B7SZLL34.SGD","LU0795875169.SGD","LU1267930813.SGD","LU1718418525.SGD","IE00B42XCP33.USD","IE00BJJMRZ35.SGD","LU0345770308.USD","LU1244550577.SGD","LU2129689514.USD","AMGN","BK4599"],"gpt_icon":0},{"id":"2513290921","title":"【MSCI北歐國家指數收漲超1%，諾和諾德漲約6%，美國藥監局稱減肥藥供應短缺問題得到處置】明晟公司MSCI北歐國家指數漲1.3%，創2月6日以來最佳單日表現，報389.62點，本週累計上漲將近3.16%。諾和諾德漲5.8%，領跑一眾成分股。2月21日稍早，美國食品藥品管理局宣稱，減肥和糖尿病藥物Ozempic短缺已得到解決，諾和諾德現在可以滿足全美範圍內對Ozempic和Wegovy的需求。巴克萊分析師Emily Field在報告中寫道，這對諾和諾德來説非常重要，因為其擴大規模的努力已經達到了“公司現在能夠供應市場”的程度。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513290921","media":"金融界","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513290921?lang=zh_tw&edition=fundamental","pubTime":"2025-02-22 00:46","pubTimestamp":1740156413,"startTime":"0","endTime":"0","summary":"明晟公司MSCI北欧国家指数涨1.3%，创2月6日以来最佳单日表现，报389.62点，本周累计上涨将近3.16%。诺和诺德涨5.8%，领跑一众成分股。2月21日稍早，美国食品药品管理局宣称，减肥和糖尿病药物Ozempic短缺已得到解决，诺和诺德现在可以满足全美范围内对Ozempic和Wegovy的需求。巴克莱分析师Emily Field在报告中写道，这对诺和诺德来说非常重要，因为其扩大规模的努力已经达到了“公司现在能够供应市场”的程度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"be3201d4ba339139b8fa1c56337988b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22004648320962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0708995401.HKD","LU1093756168.USD","LU2265009873.SGD","LU0175139822.USD","IE00BZ1G4Q59.USD","LU1267930730.SGD","LU0320765059.SGD","BK4599","LU0154236417.USD","BK4007","LU2095319765.USD","BK4588","LU1804176565.USD","LU0289739343.SGD","LU1093756325.SGD","LU0289960550.SGD","LU0289961442.SGD","LU2210149790.SGD","LU2210150020.SGD","BK4585","MSCI","LU0672654240.SGD","LU0109391861.USD","BK4532","NVO","BK4112","LU0511384066.AUD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2513297000","title":"諾和諾德股價上漲 此前FDA表示Ozempic短缺已得到解決","url":"https://stock-news.laohu8.com/highlight/detail?id=2513297000","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513297000?lang=zh_tw&edition=fundamental","pubTime":"2025-02-22 00:41","pubTimestamp":1740156067,"startTime":"0","endTime":"0","summary":"诺和诺德股价一度上涨6.4%，此前美国监管机构称，这家丹麦公司的减肥和糖尿病药物不再供应短缺。\n　　美国食品和药物管理局周五表示，诺和诺德现在可以满足全国范围内对Ozempic和Wegovy的需求。\n　　巴克莱分析师Emily Field在报告中写道，这对诺和诺德来说非常重要，因为其扩大规模的努力已经达到了“公司现在能够供应市场”的程度。\n　　该股自6月触及纪录高点以来仍下跌39%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：李桐","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"be3201d4ba339139b8fa1c56337988b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-02-22/doc-inemhpix8039144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4007","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4599","BK4588","LU0154236417.USD","LU1093756168.USD","BK4585","NVO","BK4532","LU1093756325.SGD"],"gpt_icon":0},{"id":"2513953292","title":"諾和諾德的 Wegovy 和 Ozempic 從美國 FDA 的短缺藥品名單中刪除，複方製劑生產商收到通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2513953292","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513953292?lang=zh_tw&edition=fundamental","pubTime":"2025-02-22 00:08","pubTimestamp":1740154133,"startTime":"0","endTime":"0","summary":"更新 3-诺和诺德的 Wegovy 和 Ozempic 从美国 FDA 的短缺药品名单中删除，复方制剂生产商收到通知诺和诺德表示，两种药物的所有剂量都在定期发货复配商获得 60 至 90 天宽限期Hims & Hers 股价下跌 21第 7 段增加了分析师评论，第 4 段增加了 FDA 声明，第 10 段增加了诺和诺德声明Patrick  Wingrove/Bhanvi Satija. 路透社2月21日 - 美国食品和药物管理局周五表示，诺和诺德公司广受欢迎的减肥药和糖尿病药Wegovy和Ozempic已不再短缺，这一声明将抑制复方药店生产的廉价仿制药的广泛销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"be3201d4ba339139b8fa1c56337988b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3S3PC1H1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2491049909.HKD","SG9999014906.USD","SGXZ81514606.USD","LU1366192091.USD","BK4534","LLY","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4585","LU1988902786.USD","SGXZ31699556.SGD","LU1989771016.USD","LU0823416689.USD","LU0708995401.HKD","IE00BJJMRZ35.SGD","SG9999013999.USD","SG9999015978.USD","BK4533","IE00BJLML261.HKD","LU2237443978.SGD","LU1064131342.USD","LU0820561818.USD","LU0466842654.USD","LU0198837287.USD","LU1804176565.USD","SG9999001176.SGD","LU2237443465.HKD","LU1023059063.AUD","LU0289739699.SGD","LU0471298694.HKD","LU1712237335.SGD","LU0203201768.USD","LU2461242641.AUD","WW","LU2237443895.HKD","LU1127390331.HKD","LU2023250504.SGD","LU0882574139.USD","IE00BJT1NW94.SGD","LU0456855351.SGD","BK4196","LU2211815571.USD","BK4588","SG9999014914.USD","LU1868837136.USD","BK4599","HIMS","LU0943347566.SGD","LU0061475181.USD","LU0689472784.USD"],"gpt_icon":1},{"id":"2513292688","title":"安進漲0.69% 股價突破300美元大關","url":"https://stock-news.laohu8.com/highlight/detail?id=2513292688","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513292688?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 23:48","pubTimestamp":1740152906,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日23时48分，安进股票出现波动，股价大幅上涨0.69%。截至发稿，该股报300.00美元/股，成交量36.4454万股，换手率0.07%，振幅0.92%。安进股票所在的制药行业中，整体涨幅为1.19%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。该信息摘要如下：2025年2月12日，美国特拉华州联邦法院作出裁定，安进成为和铂医药专利维权案中的新被告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221234826962b8c9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221234826962b8c9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023059063.AUD","LU2242652126.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","AMGN","BK4534","IE00BJT1NW94.SGD","LU0122379950.USD","IE0009355771.USD","BK4588","LU1983299246.USD","LU2242646821.SGD","LU0289739699.SGD","LU0868494617.USD","LU1057294990.SGD","BK4139","LU1061106388.HKD","LU0889565916.HKD","BK4566","LU0109394709.USD","BK4585","BK4581","LU0058720904.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","SG9999001440.SGD","LU1571399168.USD","IE00BFTCPJ56.SGD","BK4533","BK4599","LU2112291526.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2513994992","title":"諾和諾德(NVO.N)：美國食品藥品監督管理局（FDA）批准的所有劑量的司美格魯肽（semaglutide）正在持續出貨","url":"https://stock-news.laohu8.com/highlight/detail?id=2513994992","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513994992?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 23:09","pubTimestamp":1740150597,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4007","LU1093756168.USD","IE00BKVL7J92.USD","BK4599","IE00BZ1G4Q59.USD","NVO","BK4585","BK4532","LU0154236417.USD","BK4588","LU1093756325.SGD"],"gpt_icon":0},{"id":"2513962992","title":"諾和諾德(NVO)反覆升近4% 美國FDA稱司美格魯肽注射液Ozempic短缺已得到解決","url":"https://stock-news.laohu8.com/highlight/detail?id=2513962992","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513962992?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 22:45","pubTimestamp":1740149137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德(NVO)股价反复走高，截止发稿，涨3.9%，报87美元，成交额1.88亿美元。消息面上，美国食品药品监督管理局（FDA）称司美格鲁肽注射液Ozempic短缺已得到解决。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/Mjg1NzQ1OGJhMDJiZWVjMjcxYjFlYjJjMTY3ODIxNTA4Njc=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Mjg1NzQ1OGJhMDJiZWVjMjcxYjFlYjJjMTY3ODIxNTA4Njc=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"285690","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4532","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","BK4599","LU1093756168.USD","IE00BKVL7J92.USD","BK4007","NVO"],"gpt_icon":0},{"id":"2513951142","title":"特朗普媒體科技集團(DJT.O)漲2%，公司董事會投票決定推進擴張計劃。諾和諾德(NVO.N)漲4.9%，美國食品藥品管","url":"https://stock-news.laohu8.com/highlight/detail?id=2513951142","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513951142?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 22:32","pubTimestamp":1740148335,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0154236417.USD","IE00BZ1G4Q59.USD","BK4599","BK4532","BK4588","IE00BKVL7J92.USD","BK4077","NVO","LU1093756325.SGD","TRUMP.USD.CC","BK4547","LU1093756168.USD","DJT","BK4007","BK4516","BK4585"],"gpt_icon":0},{"id":"2513937372","title":"諾和諾德(NVO.N)盤前上漲5.5%，美國食品藥品監督管理局（FDA）稱，司美格魯肽注射液Ozempic短缺已得到解決","url":"https://stock-news.laohu8.com/highlight/detail?id=2513937372","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513937372?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 22:18","pubTimestamp":1740147539,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0154236417.USD","LU1093756325.SGD","BK4585","LU1093756168.USD","BK4588","IE00BZ1G4Q59.USD","BK4007","IE00BKVL7J92.USD","BK4532","NVO","BK4599"],"gpt_icon":0},{"id":"2513161267","title":"隱瞞關鍵信息，諾和諾德索賠8.3億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513161267","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513161267?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 21:09","pubTimestamp":1740143366,"startTime":"0","endTime":"0","summary":"近日，丹麦制药企业诺和诺德的一则诉讼案引起业内广泛关注。诺和诺德拟向一家总部位于新加坡的Biotech企业KBP Biosciences索赔8.3亿美元。隐瞒关键临床试验信息时间回到2023年，诺和诺德曾于当年10月以13亿美元的高价从KBP引进了一款用于治疗高血压和肾病药物Ocedurenone。此外，诺和诺德向法院提交的资料还显示，KBP完成这一交易后向其控股公司转移了总计3.391亿美元的资金，并宣布派发5.785亿美元的股息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221210955988dc973&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221210955988dc973&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","BK4007","LU1093756168.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4532","BK4585","LU1093756325.SGD","BK4588","IE00BKVL7J92.USD","NVO"],"gpt_icon":1},{"id":"2513430232","title":"禮來(LLY.US)新一代減肥藥可顯著減重 副作用同樣明顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2513430232","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513430232?lang=zh_tw&edition=fundamental","pubTime":"2025-02-21 15:01","pubTimestamp":1740121288,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，几名参加礼来新一代减肥药Retatrutide三期试验的患者表示，虽然他们看到体重出现了显著下降，但该药物也带来了明显的副作用。另一名试验参与者表示，其体重下降了很多，医生告诉他要多吃高热量的食物。礼来正在研发的GLP-1/GIP/GCG三靶点激动剂Retatrutide被视为迭代替尔泊肽的下一代产品。试验数据显示，相比替尔泊肽，Retatrutide的2期数据表现更加惊人——在2期临床试验中，Retatrutide的平均体重减轻率从基线开始，在24周时为17.5%，在48周时为24.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1252642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1551013425.SGD","LU1868836757.USD","LU2023250504.SGD","LU0943347566.SGD","LU0471298777.SGD","SG9999014906.USD","SG9999013999.USD","LU0320765059.SGD","LU2491050071.SGD","BK4007","LU0058720904.USD","LU0471298694.HKD","LU1983299246.USD","SG9999014914.USD","LU2361045086.USD","LU0094547139.USD","SG9999015986.USD","LU0198837287.USD","LU1868836591.USD","LU0456855351.SGD","IE00BJT1NW94.SGD","LU1623119135.USD","LU1868837300.USD","LU0640476718.USD","IE00B2B36J28.USD","LU0238689110.USD","LU1127390331.HKD","LU2211815571.USD","LU2324357040.USD","LU0466842654.USD","LU0289739699.SGD","LU2237443382.USD","SGXZ81514606.USD","IE0002141913.USD","LU1804176565.USD","LU2357305700.SGD","LU1868837136.USD","LU2237443549.SGD","LU0203201768.USD","LU1280957306.USD","LU2237438978.USD","IE0004445239.USD","LU1814569148.SGD","LU2112291526.USD","SG9999017495.SGD","LU1974910355.USD","LU1267930730.SGD","BK4599","LU0097036916.USD"],"gpt_icon":0},{"id":"2512468178","title":"21健訊Daily 丨降糖版司美格魯肽或致失明？諾和諾德回應；真實生物再闖港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2512468178","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512468178?lang=zh_tw&edition=fundamental","pubTime":"2025-02-20 09:45","pubTimestamp":1740015923,"startTime":"0","endTime":"0","summary":"政策动向广西壮族自治区药监局“十措施”助推医药产业首季“开门红”2月18日，国家药监局官网显示，近日，广西壮族自治区药监局出台研制有发展潜力中药材标准、优化医疗器械技术审评机制、支持药品医疗器械出口贸易等10条措施，充分发挥部门职能作用和技术优势，全力支持服务广西医药产业高质量发展，助推广西第一季度医药产业“开门红”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502203324544484.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502203324544484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","NVO","LU1093756325.SGD","BK4585","BK4599","LU1093756168.USD","BK4588","LU0154236417.USD","BK4532"],"gpt_icon":1}],"pageSize":16,"totalPage":7,"pageCount":7,"totalSize":112}]}}